Area of research
Virology · Infectious Diseases
Research interest
Research interests include HIV Research and Treatment, HIV/AIDS Research and Interventions, HIV/AIDS drug development and treatment, and Immune Cell Function and Interaction.
Bayesian estimation of HIV acquisition dates for prevention trials
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
Individual Differences in CD4/CD8 T-Cell Ratio Trajectories and Associated Risk Profiles Modeled From Acute HIV Infection
Examining oral pre-exposure prophylaxis (PrEP) literacy among participants in an HIV vaccine trial preparedness cohort study
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Multi-omics analyses reveal that HIV-1 alters CD4+ T cell immunometabolism to fuel virus replication
Abrupt and altered cell-type specific DNA methylation profiles in blood during acute HIV infection persists despite prompt initiation of ART
The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination
Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
Global variability of the human IgG glycome
Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting
Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
Co-Administration of HIV Env Protein with DNA and/or NYVAC Vaccines in Humans Results in Earlier and Potent Generation of Anti-Env Antibody Responses
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
Noninfectious Comorbidity in the African Cohort Study
Structural and functional brain imaging in acute HIV
Human Immunodeficiency Virus (HIV)-Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children
Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site
T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120